Q4 2025 Drug Landscape: New FDA Approvals, Label Changes, and Biosimilars
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh Q4 2025 brings meaningful FDA activity across high-cost therapeutic areas, along […]
Articles
Making Sense of MAP, PAP, and CAP Programs
By: Kevin Kobielski, President of Navion As specialty drug costs continue to rise, alternative funding programs like Manufacturer Assistance Programs
Breaking Down Outpatient Infusion Costs: Billing, Site of Care and Savings Paths
By Jason Peterson, RPh and Beckie Fenrick, PharmD, MBA Infused and injectable therapies play a critical role in treating complex conditions, but they also represent some of
Why PBM Contracts That Look Good on Paper Can Cost You More in Reality
By: Kevin Kobielski, President of Navion At first glance, many pharmacy benefit proposals can feel impressive—thick with rebate guarantees, discount percentages, and
Precision Medicine in Practice: The Growing Value of Pharmacogenomic (PGx) Testing
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh As pharmacy costs climb and personalization reshapes every corner of healthcare,
Transparent vs. Traditional PBMs: What’s the Best Choice?
By: Kevin Kobielski, President of Navion In the world of pharmacy benefits, “transparency” has become a golden word—implying clarity, fairness,
The Rise of Direct-to-Consumer Drug Pricing
Direct-to-consumer pharmacy programs aren’t new—but they’re about to get a lot bigger. Pharmaceutical manufacturers offer select medications directly to patients at flat or discounted
